Cipher Pharma Announces Retirement Of CFO Norm Evans

MISSISSAUGA, ON, April 22, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Norm Evans, Chief Financial Officer, will be retiring from the Company. Mr. Evans will remain in his current role to ensure a smooth transition of responsibilities, and the Company has commenced a formal search process for a new CFO.

"Norm has been an important part of Cipher's growth and success since 2007, and on behalf of the Board and all the employees, I want to thank him for his service to the Company and wish him well in retirement," said Shawn O'Brien, President & Chief Executive Officer. "We have built a strong finance team and capabilities to support the growth of the business and our evolution to an integrated dermatology company. Norm will work closely with the finance team to ensure a seamless and successful transition."Along with the strong finance team he has built, will ensure a seamless transition."

"I am very proud of what we have accomplished at Cipher and thankful to have spent almost 10 years with the company," said Mr. Evans. "With a growing portfolio of marketed products, a pipeline of late-stage assets, and a strong financial foundation, Cipher is well positioned for future growth. I wish Shawn and the team continued success."

About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals (NASDAQ:CPHR; TSX:CPH) is a rapidly growing specialty pharmaceutical dermatology company with a diversified portfolio of commercial-stage products with the goal of becoming the most customer-centric dermatology company in North America.

Cipher completed seven transactions in 2015, including the acquisition of Innocutis and its nine branded dermatology products, to build its U.S. commercial presence, expand its Canadian dermatology franchise and broaden its pipeline. Cipher is well-capitalized to drive long-term, sustained earnings growth by leveraging its proven clinical development capabilities and efficient commercial execution. For more information, visit www.cipherpharma.com.

Back to news